Kayothera specializes in inhibiting two of the last remaining nuclear receptors pathways to be drugged – the retinoid and rexinoid nuclear receptors. These pathways are clinically validated to drive adverse cardiometabolic and cancer outcomes, yet have no available inhibitors – until now.
Kayothera’s unique approach blocks the formation of the retinoid or rexinoid nuclear ligands with novel, orally-available small molecules that have proven to be safe and effective medicines. We are developing these medicines to provide patients with new options for managing diabetes, obesity and cancer.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 2815 Eastlake Ave E., Suite 300, Seattle,wa 98102,united States
- Phone
- (908) 731-6610
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- kayothera.com
- HQ
- Seattle, WA
Kayothera Questions
Kayothera's helpline number is (908) 731-6610
Kayothera's website is kayothera.com
Kayothera's LinkedIn profile is https://www.linkedin.com/company/kayothera
Kayothera has
6 employees.
View email and phone details for 6
employees at Kayothera.
Kayothera's industry is
Biotechnology Research
Kayothera's top competitors are
Rocket Pharmaceuticals,
Optimeos Life Sciences,
Pds Biotechnology,
Nuvectis Pharma,
Bioaegis Therapeutics, Inc.,
Automera,
Accelerator Life Science Partners,
Celularity Inc.,
Evrys Bio,
Iveric Bio, An Astellas Company.
Kayothera's categories are Biotechnology Research
Kayothera's founding year is 2019
